Drug therapy reviews: drug therapy of status epilepticus.
Drug treatment of status epilepticus is reviewed. Tonic-clonic, focal motor, complex partial and absence status epilepticus are discussed. In managing tonic-clonic status epilepticus one should: (1) maintain vital functions at all times, (2) identify and treat precipitating factors and (3) administer an intravenous loading dose of phenytoin sodium or phenobarbital sodium. Careful use of i.v. diazepam sometimes helps to achieve these objectives. Intravenous phenytoin sodium and phenobarbital sodium provide definitive, long-term control of tonic-clonic seizures but must be administered slowly and require time to reach peak brain concentrations. Intravenous diazepam appears to enter and exit from the brain rapidly and may control seizures while therapeutic brain concentrations of long-acting drugs are being achieved. Phenytoin, phenobarbital and diazepam should not be administered intramuscularly in treating status epilepticus. Treatment of focal motor and complex partial status epilepticus is similar to that of tonic-clonic status epilepticus, but i.v. diazepam is required less frequently and loading doses of phenytoin and phenobarbital sometimes can be given more slowly. Status epilepticus of the absence type is managed with i.v. acetazolamide sodium or diazepam. Paraldehyde, muscle relaxants, general anesthesia and lidocaine may be tried when conventional therapies fail.
D000768:Anesthesia, General; D003975:Diazepam / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D004828:Epilepsies, Partial / Q000188:drug therapy; D004832:Epilepsy, Absence / Q000188:drug therapy; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000627:therapeutic use; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use; D010242:Paraldehyde / Q000627:therapeutic use; D010634:Phenobarbital / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D013226:Status Epilepticus / Q000188:drug therapy*
D003473:Neuromuscular Nondepolarizing Agents; D010672:Phenytoin; D008012:Lidocaine; D003975:Diazepam; D010242:Paraldehyde; D010634:Phenobarbital